Residency · Residency · Medical Genetics Genomics
Cell-Free DNA Screening: Performance, Pitfalls, and Counseling
Overview
Cell-free DNA (cfDNA) screening, also called noninvasive prenatal screening (NIPS) or noninvasive prenatal testing (NIPT), analyzes fragments of placental (trophoblast-derived) DNA circulating in maternal blood. The test is available from 9-10 weeks gestation onward. The cfDNA in maternal blood is predominantly maternal in origin, with the fetal fraction (actually placental in derivation) typically representing 5-20% of total cfDNA. This is a screening test, not a diagnostic test, and positive results require confirmatory invasive testing via chorionic villus sampling or amniocentesis. It offers the highest sensitivity and specificity of any screening test for trisomies 21, 18, and 13.
Biology of Cell-Free Fetal DNA
Source and Characteristics
Cell-free DNA originates from apoptosis of trophoblast cells in the placenta rather than directly from the fetus. This distinction is critical because cfDNA reflects the placental genotype, which may differ from the fetal genotype in cases of confined placental mosaicism. The cfDNA fragments are short, approximately 166 base pairs corresponding to nucleosomal units. Fetal fraction increases with gestational age, typically reaching 10-15% at 10-12 weeks. Because cfDNA is rapidly cleared from maternal circulation with a half-life of approximately 1-2 hours, results reflect the current pregnancy only.
Fetal Fraction
A minimum fetal fraction of approximately 3-4% is required for reliable test performance. Causes of low fetal fraction include early gestational age, high maternal BMI (through a dilution effect), and certain aneuploidies (trisomy 13 and 18 may have lower placental cell turnover). Low fetal fraction may itself serve as a risk factor for adverse outcomes including preeclampsia and growth restriction. Some platforms report fetal fraction while others do not. Critically, a test failure due to low fetal fraction should never be considered a negative result.
<image>Diagram showing the biological basis of cell-free DNA screening, including trophoblast apoptosis releasing placental DNA fragments into maternal circulation, with distinction between maternal and fetal cfDNA contributions</image>
Screening Methodologies
Whole-Genome Sequencing (Counting/Shotgun Approach)
Massively parallel shotgun sequencing (MPSS) sequences all cfDNA fragments and counts reads mapping to each chromosome. Over-representation or under-representation of a particular chromosome indicates potential aneuploidy; for example, excess chromosome 21 reads suggest trisomy 21. This approach does not specifically distinguish fetal from maternal reads. Platforms include Illumina-based systems such as Verifi and MaterniT21.
Targeted Approaches
SNP-based approaches analyze single nucleotide polymorphism patterns at specific loci to distinguish fetal from maternal alleles, enabling determination of fetal fraction, zygosity, triploidy, and parental origin of aneuploidy (platform: Natera Panorama). Targeted sequencing approaches sequence specific regions of interest (chromosomes 21, 18, 13, X, Y) and may offer faster turnaround and lower sequencing costs. Microarray-based methods use hybridization-based capture.
Single-Gene Disorder Screening
Emerging applications allow screening for select single-gene conditions such as skeletal dysplasias and sickle cell disease by detecting paternally inherited or de novo variants in cfDNA. These applications are not yet standard of care but are rapidly evolving.
Screening Performance
Common Aneuploidies
For trisomy 21, detection rates exceed 99% with a false-positive rate of 0.04% and a positive predictive value (PPV) in the general population of approximately 80-90% (age-dependent). Trisomy 18 detection rates are 96-99% with similar false-positive rates and PPV of 60-80%. Trisomy 13 detection is 91-99% with PPV of 40-60%. Monosomy X is detected in 90-95% of cases with a false-positive rate of 0.2-0.5% and PPV of 30-50%. Other sex chromosome aneuploidies (XXX, XXY, XYY) are detected in 85-95% with variable PPV of 40-70%.
Positive Predictive Value (PPV)
PPV depends heavily on prior probability (maternal age, ultrasound findings, prevalence). In low-risk populations, even highly specific tests have lower PPV due to Bayesian principles. For trisomy 21 in a 25-year-old woman, PPV may be 50-80%, while in a 40-year-old it exceeds 95%. PPV is much lower for rarer conditions including trisomy 13, sex chromosome aneuploidies, and microdeletions. Clinicians must understand that a positive cfDNA result is not equivalent to a diagnosis.
Microdeletion Screening
Some platforms offer screening for microdeletion syndromes including 22q11.2 (DiGeorge), 5p- (Cri-du-chat), 15q (Prader-Willi/Angelman), 1p36, and 4p- (Wolf-Hirschhorn). Performance is significantly inferior to common aneuploidy screening, with PPV typically very low (2-20%) in unselected populations. ACOG, SMFM, and ACMG have expressed concerns about routine microdeletion screening due to high false-positive rates. Such screening should not be offered without appropriate pre-test counseling about limitations.
| Condition | Detection Rate | False-Positive Rate | PPV (General Population) | PPV (High-Risk) |
|---|---|---|---|---|
| Trisomy 21 | >99% | 0.04% | 80–90% (age-dependent) | >95% |
| Trisomy 18 | 96–99% | 0.04% | 60–80% | >90% |
| Trisomy 13 | 91–99% | 0.04% | 40–60% | 70–90% |
| Monosomy X (45,X) | 90–95% | 0.2–0.5% | 30–50% | Variable |
| Sex chromosome aneuploidies (XXX, XXY, XYY) | 85–95% | Variable | 40–70% | Variable |
| 22q11.2 microdeletion | ~75% | ~0.5% | 2–20% | Higher if ultrasound findings |
<image>Graph comparing positive predictive values of cfDNA screening for trisomy 21, trisomy 18, trisomy 13, and 22q11.2 microdeletion across different maternal age groups, illustrating the impact of prior probability on PPV</image>
Sources of Discordant Results
False Positives
Confined placental mosaicism (CPM), where trisomy is present in the placenta but not the fetus, is the most common cause of false-positive cfDNA results. Maternal chromosomal mosaicism can contribute aneuploid maternal cells to the cfDNA pool. Maternal copy number variants (microdeletions or microduplications) may be detected as apparent "fetal" findings. Occult maternal malignancies that shed aneuploid DNA into the circulation may present as unexpected chromosomal abnormalities on cfDNA screening. A vanishing twin's placental DNA can persist in maternal circulation for weeks after demise.
False Negatives
False negatives can result from low fetal fraction providing insufficient signal, true fetal mosaicism with low-level aneuploidy, partial aneuploidy or structural rearrangements not detected by the platform, or technical limitations in detecting triploidy (which most platforms cannot reliably identify).
Special Situations
In twin pregnancies, cfDNA screening is less well-validated; fetal fraction per twin is lower, and discordant results are possible in dizygotic pairs. Donor egg or surrogacy arrangements require specific configurations for SNP-based platforms, though shotgun approaches are generally unaffected. Maternal organ transplants may shed donor cfDNA that confounds results. Rare cases of maternal aneuploidy (such as mosaic trisomy X) have been reported.
Professional Society Recommendations
ACOG/SMFM (2023)
cfDNA screening should be offered to all pregnant individuals regardless of age or risk status, with emphasis that it remains a screening test. Diagnostic testing should be available to all who desire it. Pre-test counseling should cover the distinction between screening and diagnostic testing, the possibility of false positives and negatives, and limitations for microdeletions. Positive cfDNA results should be confirmed by diagnostic testing before any irreversible clinical decisions.
ACMG (2022 Update)
ACMG recommends offering cfDNA to all pregnancies as the most sensitive screening option for trisomies 21, 18, and 13. They recommend genome-wide cfDNA over targeted approaches when available, but recommend against routine microdeletion screening without individual clinical indication.
<image>Counseling framework infographic for pre-test and post-test cfDNA screening discussions, including key messages about screening versus diagnosis, PPV limitations, and next steps for positive, negative, and no-result outcomes</image>
Counseling Considerations
Pre-Test Counseling
Pre-test discussions should explain the screening versus diagnostic test distinction, identify which conditions are being screened and their performance characteristics, address what positive, negative, and no-result outcomes would mean, and discuss the option of proceeding directly to diagnostic testing. Patients should be informed about possible incidental findings (sex chromosome aneuploidies, maternal CNVs, vanishing twin, occult maternal malignancy) and should have the opportunity to opt in or out of sex chromosome aneuploidy screening.
Post-Test Counseling for Positive Results
When results are positive, counseling must emphasize that a positive screening result is not a diagnosis. The PPV should be calculated and communicated based on the specific finding and clinical context. Confirmatory diagnostic testing (amniocentesis preferred for most conditions; CVS for earlier results) should be offered. Language such as "your baby has Down syndrome" must be avoided based on screening alone. Balanced, nondirective counseling about the condition should be provided along with connections to support resources and parent groups.
No-Result/Test Failure
Test failure occurs in 1-5% of cases, most commonly due to low fetal fraction. A repeat draw may be offered with a success rate of approximately 50-60%. Low fetal fraction is not a benign finding and is associated with increased risk of aneuploidy, preeclampsia, and adverse outcomes. Alternative screening (second-trimester serum screening, detailed ultrasound) or diagnostic testing should be offered. ACOG recommends genetic counseling and consideration of diagnostic testing after a no-result.
Clinical Pearls
cfDNA screens the placenta, not the fetus -- this is the fundamental concept underlying both false-positive and false-negative results. A "no-call" or test failure is not a negative result and warrants follow-up with genetic counseling and consideration of diagnostic testing. Positive cfDNA results must always be confirmed with diagnostic testing before any irreversible decisions including pregnancy termination. Multiple chromosome abnormalities flagged on cfDNA should raise suspicion for maternal malignancy or maternal mosaic aneuploidy. In twin pregnancies, if one twin is trisomic and the other euploid, cfDNA may show a borderline or atypical result given lower sensitivity in multiple gestations. The detection of 22q11.2 deletion on cfDNA has a PPV of only approximately 5-10% in average-risk pregnancies, requiring extensive counseling. Genome-wide cfDNA analysis can increasingly detect large deletions, duplications, and rare autosomal trisomies, but with lower PPV and less clinical validation.
References
- Gil MM, Accurti V, Santacruz B, et al. "Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis." Ultrasound in Obstetrics & Gynecology. 2017;50(3):302-314.
- ACOG Practice Bulletin No. 226: "Screening for fetal chromosomal abnormalities." Obstetrics & Gynecology. 2020;136(4):e48-e69.
- Gregg AR, Skotko BG, Benkendorf JL, et al. "Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the ACMG." Genetics in Medicine. 2016;18(10):1056-1065.
- Bianchi DW, Chudova D, Sehnert AJ, et al. "Noninvasive prenatal testing and incidental detection of occult maternal malignancies." JAMA. 2015;314(2):162-169.
- Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. "Circulating cell free DNA testing: are some test failures informative?" Prenatal Diagnosis. 2015;35(3):289-293.
